SciSparc Announces Deeply Discounted $0.77M Offering Amid Nasdaq Delisting Threat
Summary
SciSparc Ltd. is conducting a registered direct offering of 766,170 ordinary shares at a significant discount, raising approximately $0.7 million, while simultaneously facing a Nasdaq delisting notice due to a stockholders' equity deficit.
Key Events
-
Registered Direct Offering
SciSparc is offering 766,170 ordinary shares to certain institutional and accredited investors.
-
Deep Discount Pricing
Shares are priced at $1.00, a significant discount to the last reported sale price of $1.45 on January 12, 2026, and today's price of $1.12.
-
Substantial Dilution
The offering will increase the number of outstanding shares by approximately 21.37%.
-
Nasdaq Non-Compliance
The company received a notice on January 12, 2026, for failing to meet Nasdaq's minimum stockholders' equity requirement, reporting a deficit of approximately $81,000 as of June 30, 2025.
Analysis
This offering is a critical financing event for SciSparc, providing approximately $0.7 million in net proceeds for working capital and general corporate purposes. However, the offering is highly dilutive, increasing outstanding shares by over 21%, and is priced at a substantial discount to recent trading prices, indicating the company's urgent need for capital. The timing coincides with a Nasdaq notification of non-compliance with minimum stockholders' equity requirements, highlighting severe financial distress and a significant risk of delisting. While the capital raise provides a short-term lifeline, the terms and underlying financial issues present a strong negative signal for investors.
At the time of this filing, SPRC was trading at $1.12 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $4M. The 52-week trading range was $1.00 to $19.09. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.